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Nearly a half a million women throughout the world develop cervical cancer every year Parkin and Bray (“Chapter 2. The
burden of HPVrelated cancers,” Vaccine, vol. 24, no. 3, pp. S11–S25, 2006); 80% of these women are in countries without a
quality-assured cytology screening program. It is in this setting that Cervarix could reduce the incidence of cervical cancer to
about 9.5/100,000 women. New evidence indicates that this might be able to be accomplished with a single dose of Cervarix,
a great advantage to public health implementation programs Kreimer et al. (“Proof-of-principle evaluation of the eﬃcacy of
fewer than three doses of a bivalent HPV16/18 vaccine, The Journal of the National Cancer Institute, vol. 103, no. 19, pp. 1444–
1451, 2011). In countries with screening programs, adenocarcinoma is the most diﬃcult to detect and treat with later-stage
presentation and higher mortality Smith et al. (“The rising incidence of adenocarcinoma relative to squamous cell carcinoma
of the uterine cervix in the United States—a 24-year population-based study,” Gynecologic Oncology, vol. 78, no. 2, pp. 97–105,
2000) and Gunnell et al. (“A longitudinal Swedish study on screening for squamous cell carcinoma and adenocarcinoma: evidence
of eﬀectiveness and overtreatment,” Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 12, pp. 2641–2648, 2007). With
additional cross-protection to HPV 31, 33, and 45 and protection against HPV 16 and 18 lasting at least 9.4 years, Cervarix
may reduce adenocarcinomas in screened populations by more than 90%. This paper will detail the evidence about the eﬃcacy,
immunogenicity, and safety of Cervarix in the studied populations contrasting public health goals with individual health options.
1.Introduction
Cervical cancer is unequivocally initiated by a human
papillomavirus (HPV) infection, but much less than 1%
of HPV infections progress to cervical cancer [1]. This
inconsistency has made the cervix the site most studied of all
HPVinfections.TheﬁrstassociationsofHPVinfectionswith
cervical cancer specimens were made by zur Hausen [2]a n d
Meisels and Fortin [3]. Multiple case control, cohort, and,
ﬁnally, prospective longitudinal studies have provided much
detail in concert with biochemical mechanistic studies about
the steps of HPV infection and where they branch to onco-
genesis. This paper will detail the eﬃcacy, immunogenicity,
and safety of Cervarix as it pertains to interruption of the
infection process to prevent cervical cancer.
1.1. Low- versus High-Risk HPV Types. The carcinogenic
risk potential of the mucosal alpha genus HPV types is
categorized as low or high-risk. Low- and high-risk types
were so classiﬁed based on their propensity to be associated
with cervical cancer. High risk types had odds ratios of
association with cervical cancer in the hundreds, much
higher than the odds ratios found linking tobacco use and
lung cancer [4]; low-risk types had odds ratios around one,
indicating very little to no risk of malignant transformation
[5]. The designation of high-risk types has been inconsistent
in the International Agency for Research on Cancer (IARC)
monographs, but has most recently included four species
(5, 6, 7, and 9) of the alpha genus of papillomaviruses.
The twelve HPV types considered carcinogenic by current
evidence include one from species 5 (HPV 51), one from
species 6 (HPV 56), four from species 7 (HPV 18, 39, 45,
and 59), and six from species 9 (HPV 16, 31, 33, 35, 52, and
58) [6]. Of these types, HPV 16 and HPV 18 are the most
aggressively oncogenic [7].2 ISRN Obstetrics and Gynecology
1.2. Clinical Manifestations of Viral Infection. HPV presents
in a variety of clinical appearances classiﬁed in two cate-
gories: benign and oncogenic. One of the most common
diﬀerentiating factors is the expression of the E2 protein.
If E2, an early expressed HPV protein, is not disrupted,
then HPV infection most often remains episomal within the
epithelial basal cell. As an episomal infection, benign forms
such as condyloma and cervical intraepithelial neoplasia
grade 1 (CIN 1) are clinically seen, despite the type of HPV
that is causing the infection [8]. If the HPV genome is
disrupted,whichhappensmostoftenafterintegrationwithin
the human chromosome, then oncogenesis can proceed and
CIN 2/3 can occur. Only those persistent high-risk HPV
infections have the opportunity to progress to CIN 3, yet
less than half of persistent infections do progress [9]. There
is very slow progression from CIN 3 to invasive cancer [10]
with some CIN 3 regressing to normal epithelium [11].
The validity of CIN 2 being a cancer precursor is
uncertain due to high misclassiﬁcation rates [12], and poor
intra- and interobserver reproducibility in diagnosis [13],
as well as high regression rates to normal in young women
[14]. While there is considerable scientiﬁc debate around
the CIN 2 classiﬁcation, clinically CIN 2 is considered a
cancer precursor and standardly treated as such. Therefore,
the HPV vaccine trials include CIN 2 as a cancer precursor
endpoint.
1.3. Time Sequence of Events. The natural history of HPV
infections in the cervical epithelium in vivo cannot be
detected unless the infection is actively replicating. Most
actively replicating HPV infections in postpubertal females
must reach a signiﬁcant viral threshold to produce a cytolog-
ically detectable lesion [15, 16]. Hence, there is a time delay
from infection to detection of cervical cytologic abnormali-
ties. Most are detected on average between 10 and 44 months
after a HPV 16/18 infection and between 19 and 45 months
for all other high-risk HPV infections, while low-risk HPV
infections can be detected by cytology on average 10 to 55
monthsafterinfectioninyoungwomen[17–19].WhileHPV
infection is very common, with nearly a ﬁfth of all women of
screening age infected, less than 8% of screened women have
associated cytologic abnormalities [20–23]. Cell-mediated
immunologic clearance controls most infections, but not all.
70% of cytologically expressed infections will clear within
one year, and more than 90% within three years [9, 24].
Of those cytologically expressed infections that do not clear,
only half progress to precancerous cervical intraepithelial
neoplasia grade 2 or 3 (CIN 2/3) [9]. It takes ﬁve years
for 20% of the large visible CIN 3 lesions to progress to
invasive cancer, and after 30 years, only 40% of CIN 3 lesions
have become cervical cancer [10]. This is, on average, a very
slowly progressing cancer for which screening has been very
successful in preventing [25].
1.4. Natural Infection Does Not Protect against Future HPV
Infections. ThenaturalimmunologicresponseofHPVinfec-
tions is poorly understood, and its meaning is vigorously
debated. Most of the data are from studies of young
sexually active women. About half of the young women
with oncogenic HPV infections seroconvert. Of those who
do, seroconversion takes months to detect, usually at low
antibody titers [26–29] which are most often insuﬃcient to
prevent reinfection with the same HPV type [30–32]. There
is one study in young women which shows that women with
>60EU/mL of anti-HPV 16 have about half of the incident
HPV 16 infections that women with lower or nondetectable
titers develop [31]. Whether this represents a threshold
value for immunoprotection or whether this is an artifact of
antibody measurement is unknown.
HPV does not cause a viremia, and hence, as a natural
infection, it has very little chance of initiating an anamnestic
response of prior primed memory B cells. Immunologically,
HPV does not cause cell lysis in either the episomal or
integrated infection format. HPV does not incite an inﬂam-
matory response at the time of infection or reinfection;
there are no proinﬂammatory cytokines released, and there
is poor exposure and activation of the epithelial antigen-
presenting cells and Langerhans cells [33]. This lack of
immune recognition allows new infections of the same or
diﬀerent HPV types to be established.
1.5. HPV Infection by Age. HPV infection is documented by
viral DNA detection in the cervicovaginal epithelium or by
serologic evidence. Both DNA detection and serologic assays
have detected high-risk HPV infections in all ages of females
with the incidence as high as 10% in those under 11 years
of age [34–39]. Peak prevalence of high-risk HPV infection
detected by DNA testing occurs in the late teen-early 20’s
a g eg r o u pw i t he s t i m a t e sa sh i g ha s3 5 %[ 20, 22], dipping to
around 10% in the adult woman with increases in prevalence
againseenstartinginseveralpopulations ofwomenaged35–
55 years with a second peak in prevalence a decade later [20].
Most research on DNA detection of HPV infections has
focused on the highest prevalence group of females 16–25
years old attributing the peak rates to sexual activity. In
sexually active women older than 25 years, the incidence of
oncogenic HPV infections is 5 to 15% [40–42] with less than
a ﬁfth of the infections attributed to HPV 16 or 18 [40, 42–
44].Lessdatadetaillongitudinalstudiesofincidenthigh-risk
HPVinfectioninwomenolderthan40yearsanditsmeaning
vis ` a vis CIN 3 and cervical cancer progression.
Data available to date indicate that there is a real
incidence of new high-risk HPV infections that exceeds 10%
in women older than 42 years. Over a 7-year study period
these incident infections cause new CIN 3+ lesions in over
half of the HPV-infected women [45]. An equal proportion
of newly detected infections were explained by recent sexual
behavior as by past sexual behavior [46]. In women older
than 56 years, the proportion of high-risk HPV types other
than HPV 16 causing the incident CIN 3+ is much more
than for younger women (72% versus 32%), a progressive
decrease in CIN 3+ HPV 16 attribution with aging [47].
While we have no longitudinal data on the progression
of incident CIN 3 in women older than 40 years to cervical
cancer, the public registries of the Nordic countries where
screening is well organized show bimodal distributions
of incident CIN 3 and cervical cancer that are separatedISRN Obstetrics and Gynecology 3
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Figure 1: Incidence of cervical intraepithelial neoplasia grade 3
(CIN 3) and cervical cancer in Iceland. Bimodal peaks of CIN 3
incidence(yellowhighlighted)occurat25–29yearsofageandagain
at 55–59 years of age while the bimodal peaks of cervical cancer
incidence (orange highlighted) are oﬀset to ﬁve to ten years later
in the 30–34-year-olds and the 65–69-year-olds [48].
by the expected 5–10-year time lag (Figure 1). Likewise,
in countries without screening programs, the age-speciﬁc
incidence of cervical cancer continues to increase with age
(Figure 2), rather than plateauing or decreasing as would be
seen if there was no risk of cervical cancer from new HPV
exposure at an older age.
The role of past infections as a source of latent viral
reactivation for the older woman has been seriously chal-
lenged by a recent analysis of a ten-year cohort of nearly
2500 women [49]. In this study, women older than 40 years
had a similar or higher rate of high-risk HPV reinfection
from new partners compared to the initial infection rate for
the same HPV types at younger ages. These data suggest
t h a taw o m a ni sn o tf u l l yp r o t e c t e db yaﬁ r s tH P Vi n f e c t i o n
earlier in life because she is at a similar risk of acquiring both
diﬀerent high-risk HPV types and the same HPV type she
previously had seemed to clear [49]. The cause of the new
infections in women older than 40 years was correlated with
having new sexual partners only, not from past infections,
negatingtheroleoflatentviralreactivation.Inaddition,viral
loads of new infections in the previously infected women
were comparable to the viral loads of initial infections
suggesting that natural immunity also played no protective
role in reinfection with the same or diﬀerent HPV types
[49].
1.6. Continued Lifetime Risk of Cancer. Among women with
a high-risk HPV infection that progresses to a CIN 3 lesion
there is an increased risk of other anogenital cancers beyond
the cervix. Women have a 3–12-fold increased chance of
developing another anogenital cancer (vagina, vulva, anus)
within 10 years with increasing risk in the second decade
posttreatment for their CIN 3 lesion [50–52]. In addition,
cervical cancers can recur despite highly eﬀective excisional
treatments for CIN 3 [53] which is only partially explained
by incomplete excisions [54].
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Figure 2: Age-speciﬁc incidence of cervical cancer in countries
with and without screening programs. The Brazil data represent
countries without a cervical cancer cytology screening program.
The UK data support the bimodal distribution of cervical cancers
peaking at 35 and 65 years of age as seen in Figure 1. The Brazil
data show continued increases in cancer incidence through 70 years
that would be unlikely should there be no further incident HPV
infections in older women [48].
1.7. Distribution of HPV Types Changes according to the
Natural History Stage. The distribution of high-risk HPV
types varies among increasingly severe cytologic changes and
cancer. The prevalence of HPV 16 and 18, the HPV types
of most oncogenic potential, is very low among the general
population. IntheUSApopulation, HPV16 is thesixth most
prevalent infection at 1.5% with HPV 18 occurring in 0.8%
of the population [55]. Globally, the prevalence in a normal
populationisaboutthesame,2–4%,forHPV16and18[20].
Even among the highest risk group of women, the baseline
prevalence of HPV 16 and 18 DNA positivity maximizes at
9% and 4%, respectively [28, 47, 56, 57].
In contrast, the prevalence of HPV 16 and 18 increases to
27% in womenwith low-grade cytologic abnormalities (low-
grade squamous intraepithelial lesions (LSILs)) which by
deﬁnition means infection with HPV. In women with high-
grade squamous intraepithelial lesions (HSILs), the preva-
lence of 16 and 18 increases to about 50%. Finally, 67% of
the squamous cell carcinomas and 75% of adenocarcinomas
are caused by HPV 16 and 18 (Table 1)[ 58–62].
Prophylactic HPV vaccination will have little cancer-
reducing eﬀect in the general screened population, but may
prevent cervical cancer among those with no screening
opportunities. Prophylactic vaccination may help decrease
the numbers of women who develop abnormal cytology
screens among those who are screened. Modeling indicates4 ISRN Obstetrics and Gynecology
Table 1: HPV genotype distribution among women with increasingly severe cervical abnormalities.
Normal
women [62]
Women with
LSIL [58]
Women with
HSIL [59]
Women with
squamous cell
cervical carcinoma
[60]
Women with adeno- or
adenosquamous
carcinoma of the cervix
[60, 61]
HPV 16 1.8% 27% 45% 62% 39%–50%
HPV 18 0.7% 9% 7% 8% 32%
HPV 31 0.7% 12% 9% 4% 1%-2%
HPV 33 0.5% 8% 7% 4% 1%–3%
HPV 45 0.5% 5% 2% 5% 12%
Table 2: Vaccine composition of a 0.5mL dose of Cervarix [63].
Protein subunit
component Concentration Adjuvant Manufacturing components Expression system
Cervarix
HPV 16 L1 VLP 20µg AS04: 50µgo f
3-O-desacyl-4 -mono
phosphoryl lipid A
(MPL) adsorbed onto
500µga l u m i n u m
hydroxide salt
4.4mg sodium chloride Baculovirus
expression system
in Trichoplusia ni
insect cells
HPV 18 L1 VLP 20µg
0.624mg sodium dihydrogen
phosphate dihydrate
<40ng of insect cell and viral
protein
<150ng bacterial cell protein
that HPV vaccination will prevent potentially 17% of the
abnormal Pap tests based on current knowledge of HPV type
distribution (Figure 3)[ 73]a n do n l yav e r yf e wc a n c e r st h a t
P a pt e s t i n gw o u l dn o th a v ed e t e c t e d[ 74, 75], not enough to
lower the population incidence of cervical cancer lower than
what screening already accomplishes [76].
1.8. Modeled Economic Policy Implications. Cervical cancer is
the most prevalent in absolute numbers and absolute costs
of all the HPV-associated diseases. It comprises 88% of the
worldwide burden of HPV-associated cancers and consumes
92% of the monies spent on HPV-associated diseases [77–
82]. Cervical cancer represents 6.8% of all female cancers,
and 3.2% of all cancers globally [77]. Prevention of CIN 2+
and cervical cancer is the driving force for Cervarix use.
Four times as many cervical cancers occur in countries
without quality-assured screening programs as in those
countries with ongoing organized screening programs [77].
The incidence of cervical cancer in countries without
screeningrangesbetween50and80/100,000women[83,84].
Cervarix will have the highest impact in these countries
if given to young women prior to HPV exposure, which
public health authorities have targeted as the sexually naive
11-12-year-old age range. Under favorable assumptions,
Cervarix could achieve a cervical cancer incidence as low as
9.5/100,000. If the duration of vaccine eﬃcacy is less than 15
years, though, cost-eﬀectiveness analyses show that shifting
the recommended age of vaccination to 15 years becomes a
much more aﬀordable option [76, 85].
Cervical cancer incidence in countries with well-
established cytology screening programs ranges from 4 to
10/100,000 women [83], mostly below the incidence that
Cervarix can achieve. Yet, among those screened, the
incidence of CIN 3 ranges from 1.6 to 16 times the incidence
of cervical cancer [48]. In the USA the average incidence
of CIN 3 is 150/100,000 women per year with a peak
incidence around 800/100,000 women per year in the 25–
29-year age group [86]. The incidence of abnormal cytology
screensisestimatedat7800/100,000womenperyear,another
magnitude increase [23]. While public health authorities still
target the sexually naive 11-12-year-olds in countries with
screening, the beneﬁt will not be reduction of cervical cancer
incidence, but instead, a reduction in abnormal cytology
screens and incidence of CIN 3 [74]. This beneﬁt is realized
within four years of vaccination of sexually active women
[57] and is not dependent on the duration of vaccine eﬃcacy
exceedingthe15-yearthresholdoronthecoverageoffemales
or males vaccinated as documented in economic models
[76, 79, 85]. It is only by continued cytology screening,
regardlessoftheoptionofvaccination,thatthelowincidence
of cervical cancer can be maintained [74, 87].
2. Overview of the Market
Cervarix will be most eﬀective in countries without quality-
assured cervical cytology screening programs. In these
countries, Cervarix may reduce the incidence of cervical
cancer to 9.5/100,000 women if the duration of eﬃcacy
exceedsatleast15years[76].Modelersagreethatdurationof
vaccine eﬃcacy is the primary parameter determining cost-
eﬀectiveness of vaccination followed closely by the cost of
the vaccine [74, 76, 80–82, 88–100]. Given the very high
one-dose eﬃcacy seen in preliminary trials for Cervarix, the
possibility of reducing programmatic implementation costs
as well as vaccine costs makes Cervarix an attractive public
health vaccine. The competitor HPV vaccine, Gardasil,ISRN Obstetrics and Gynecology 5
Table 3: Signiﬁcant eﬃcacies for Cervarix by endpoint, population
and time of follow-up.
Endpoint Population Vaccine eﬃcacy
(96.1% CI)
Average
time of
follow-
up
Reference
6 mo persistent
infection
caused by HPV
16/18
ATP-E 100% (80, 100) 7.3 yrs [64]
12 mo
persistent
infection
caused by HPV
16/18
ATP-E 100% (56, 100) 7.3 yrs [64]
CIN 1+ caused
by HPV 16/18 ATP-E 100% (34, 100) 7.3 yrs [64]
CIN 2+ caused
by HPV 16/18 ATP-E 100% (51, 100) 8.4 yrs [65]
CIN 2+ caused
by HPV 16/18 ATP-E∗ 98% (88, 100) 48 mo [57]
CIN 3+ caused
by any HPV
type
TVC-N 93% (79–99) 48 mo [57]
6-month persistent infection is deﬁned as the detection of DNA from the
same HPV type in two consecutive cervical cytology samples collected over
any6-monthperiodand12-monthpersistenceasdetectionofthesameHPV
type in all available cytology samples collected over any 12-month period.
ATP-E means according to protocol for eﬃcacy all women who met
eligibility criteria and complied with the protocol, who received three
injections, whose baseline Pap was normal, ASCUS or LSIL, and who were
seronegativetoHPV16and18andDNA-negativeforHPV16/18atbaseline;
cases counting starting one day after the third vaccination.
ATP-E∗ means those in the ATP-E, but HPV type assignment algorithm was
used to resolve causation when multiple HPV types were present.
TVC means total vaccinated cohort: women with at least one injection,
seropositiveornegative,PCRpositiveornegativeforoneormoreHPVtypes
at baseline, regardless of Pap result; case counting starting ﬁrst day after ﬁrst
injection.
TVC-N means TVC-naive: women who received one or more vaccine dose
with normal cytology, seronegative for HPV 16/18 and DNA negative for 14
oncogenic HPV types at baseline (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 66 and 68); case counting starting ﬁrst day after ﬁrst injection.
can reduce the incidence of cervical cancer, under best
assumptions, to 14/100,000 in three doses [101].
Where cervical cancer screening programs are routinely
followed, the option to vaccinate with Cervarix may result
in a reduction of abnormal cytologies: in the USA estimates
are a reduction to 3400/100,000 women per year and CIN
3 lesions to 11/100,000 women per year. This outcome
is clinically quite valuable as it reduces the psychological
and reproductive morbidity associated with the screening
process [102]. The competitor HPV vaccine, Gardasil, may
also eﬀectively reduce abnormal cytology screening rates
to 4200/100,000 women per year and CIN 3 lesions to
42/100,000 women per year [101].
Quality assured cytology screening programs are still
the main deterrent and preventer of cervical cancer in
industrialized countries, though, not vaccination [74, 76].
The introduction of Cervarix in well-screened nations has
the potential to worsen the incidence of cervical cancer if the
population participation in the routine cytology screening
drops below 70% [74], as has already been observed [75,
103]. Until we have data to show that the duration of vaccine
eﬃcacy exceeds the threshold for public utility, ongoing
screening programs should not be altered.
An individual, not population-based or publicly fund-
ed, beneﬁt of Cervarix also includes vaccinating seroposi-
tive/DNA-negative women (women already exposed but
currently not expressing infection) and older women up to
55 years of age; these individual uses of Cervarix are highly
valued clinical options based on published study data, not
current public health targets. The competitor HPV vaccine,
Gardasil, does not oﬀer these beneﬁts [101].
3. Composition
Cervarix contains 20 micrograms each of HPV 16 and 18
L1 capsid proteins, called virus-like particles (VLPs). VLPs
are composed of self-assembling L1 major capsid proteins.
Accessibility of the conformational epitopes for antigen
presentationismaximizedbytheadjuvant,whichinturnhas
contributed to the cross-protection to three phylogenetically
related HPV types of both HPV 16 and 18.
The AS04 adjuvant was developed to mimic the Toll-
like receptor 4 agonist. This enhancement increases the
local cytokine response which results in direct stimulation
of antigen-presenting cells and subsequent cellular and
humoral immune responses which ultimately eﬀect stronger
and more enduring antibody responses [104]. AS04 contains
500 micrograms of aluminum hydroxide and 50 micrograms
of 3-O-desacyl-4 -monophosphoryl lipid A (MPL) which is
a lipopolysaccharide of Salmonella minnesota R595 [105].
AS04 has been found safe and tolerable in trials and in post-
marketing surveillance of a hepatitis B vaccine adjuvanted
with AS04 (Fendrix) used in both those with and without an
impaired immune system [63, 106, 107]. The AS04 adjuvant
system has consistently provided higher and longer antibody
titers compared to aluminum salt adjuvants both in animal
models and in human studies [63, 106–108].
There are additional manufacturing components used in
the Baculovirus expression system of Trichoplusia ni insect
cells, to result in the ﬁnal 0.5mL dose of Cervarix (Table 2)
[109]. Long-term stability of the vaccine is attributed to the
L1 VLP manufacturing process and to the AS04 adjuvant
[105, 110].
4. Efﬁcacy
Cervical cancer is the prevention goal. As it is not ethical
to allow women in a placebo arm of a trial to develop
cervical cancer when screening and treatment for CIN 2/3
and adenocarcinoma in situ (AIS) lesions is standard of care,
themost closely related surrogateendpoint to cervicalcancer
that can be studied for prevention in clinical trials is CIN 2/3
and AIS. As the mechanism of vaccine action is to prevent
HPV infection, not the development of CIN 2/3/AIS after
an infection, a second surrogate endpoint for prevention is
incident and persistent HPV infection [111].6 ISRN Obstetrics and Gynecology
Table 4: Cross protection oﬀered by Cervarix [66].
Endpoint Population Vaccine eﬃcacy
(96.1% CI)
Average time
of follow-up
6month persistent
infection TVC-N
HPV 31 77% (67, 84) 44month
HPV 33 43% (19, 60) 44month
HPV 45 79% (61, 89) 44month
CIN 2+ associated with TVC-N
HPV 31 89% (66, 98) 44month
HPV 33 82% (53, 95) 44month
HPV 45 100% (42, 100) 44month
Regardless of HPV type TVC-N 93% (79, 99) 44 months
Infection deﬁnitions: 6-month deﬁnition required the detection of the same HPV type in two consecutive cervical samples, with no negative sample in
between, over a minimum of 5 months.
CIN 2+ means cervical intraepithelial neoplasia grades 2 and 3 and adenocarcinoma insitu. Lesions may be coinfected with HPV 16/18.
TVC means total vaccinated cohort: women with at least one injection, seropositive or negative, PCR positive or negative for one or more HPV types at
baseline, regardless of Pap result; case counting starting ﬁrst day after ﬁrst injection.
TVC-N means TVC naive: women who received ≥1 vaccine dose with normal cytology, seronegative for HPV-16/18 and DNA-negative for 14 oncogenic HPV
types at baseline (16, 18, 31.33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68); case counting starting ﬁrst day after ﬁrst injection. Subjects were followedf o ra n
average 44.3 months after ﬁrst injection.
Table 5: Reduction in abnormal cytology irrespective of HPV
causation, colposcopy, and excisional treatments [57].
Population Vaccine eﬃcacy (96.1%
conﬁdence intervals)
ASCUS TVC-N 23% (17, 29)
LSIL TVC-N 24% (14, 33)
HSIL TVC-N 54% (5, 79)
Reduction in
colposcopy
exams
TVC-N 29% (22, 36)
Reduction in
excisional
procedures
TVC-N 70% (58, 79)
TVC-N means TVC naive: a TVC subset including women 15–25 years old
who received ≥1 vaccine dose with normal cytology, seronegative for HPV-
16/18 and DNA-negative for 14 oncogenic HPV types at baseline ((16, 18,
31. 33, 35, 39,45, 51, 52, 56, 58, 59, 66, and 68); case counting starting ﬁrst
dayafterﬁrstinjection.Subjectswerefollowedforanaverageof39.5months
after ﬁrst injection.
ASCUS means atypical squamous cells of undetermined signiﬁcance
irrespective of HPV type association.
LSIL means low-grade squamous intraepithelial lesion irrespective of HPV
type association.
HSIL means high-grade squamous intraepitheliallesion irrespective of HPV
type association.
Cervarix has documented high eﬃcacy against the
combination endpoint of cancer precursors CIN 2/3, AIS,
and invasive cervical cancer (CIN 2+) caused by HPV 16/18
(Table 3)[ 57, 64, 65]. This eﬃcacy lasts for at least 9.4 years.
4.1. Additional Eﬃcacy against HPV 31, 33, and 45. In
addition, Cervarix provides protection in HPV naive women
from both six- and twelve-month persistent infection, and
CIN 2+ caused by HPV 31, 33, and 45 lasting at least 8 years
(Table 4)[ 112]. This additional protection is signiﬁcant as it
provescross-protectionforbothHPV-16andHPV-18phylo-
genetically related types. The HPV-16-related types (31, 33,
52, and 58) are more commonly associated with squamous
cell carcinomas, whereas the HPV-18-related types (45 most
dominantly) are associated with adenocarcinomas. Together
HPV 45, 31, and 33 collectively account for about 15%
of invasive cervical cancers, and nearly 20% of all adeno-
or adenosquamous carcinomas, with HPV 45 being the
dominant contributor after HPV 16/18 [60].
Extrapolating from HPV distribution studies and the
cross-protection eﬃcacies, Cervarix is expected to protect
against more than 90% of adenocarcinomas, those cancers
that occur in younger women, are most diﬃcult to detect
by screening programs, present at later-stages, and thus have
higher mortality [60, 61, 66, 113]. In addition Cervarix
is expected to prevent more than 80% of squamous cell
carcinomas for a combined eﬀect of preventing over 85% of
all types of cervical cancers. This substantial impact at the
c a n c e rl e v e li ss u p p o r t e db yt r i a ld a t aa tt h eC I N2 +l e v e l
indicatinga70%eﬃcacyagainstallCIN2+lesionsregardless
of HPV type causation, which by epidemiologic studies is
expectedtobeonly50%(Table 4)[59].Endofstudyanalyses
indicate 93% eﬃcacy against all CIN 3+ lesions regardless of
HPV type causation [114].
4.2. Prevention of Abnormal Cytology, CIN 2+, and Excisional
Treatments. Among women who received Cervarix when
seronegative and DNA-negative for HPV 16/18 and who par-
ticipated in repeated cytology screening, Cervarix prevented
more than 20% of all abnormal cytology in the ﬁrst 4 years
after vaccination (Table 5)[ 57]. Cervarix prevented 26% of
the clinically indicated colposcopy exams and reduced the
rate of excisional procedures for precancerous disease by
nearly 70% [57].ISRN Obstetrics and Gynecology 7
Table 6: Vaccine eﬃcacy in women 15–25 years old who were DNA-negative for HPV 16 or 18 at baseline [67].
Endpoint Population Serostatus Vaccine eﬃcacy
(96.1% CI)
Average time of
follow-up
6-month
persistent
infection caused
by HPV 16/18
ATP-E Seropositive 81% (59, 92) 41month
12-month
persistent
infection caused
by HPV 16/18
ATP-E Seropositive 92% (64, 99) 41month
CIN 2+ caused
by HPV 16/18 ATP-E∗ Seropositive or
seronegative 99% (90, 100) 41 month
Infection deﬁnitions: 6-month deﬁnition required the detection of the same HPV type in two consecutive cervical samples, with no negative sample in
between, over a minimum of 5 months; a 12-month deﬁnition required the detection of the same HPV type at consecutive assessments, with no negative
samples in between, over a minimum of 10 months.
ATP-E means according to protocol for eﬃcacy all women who met eligibility criteria and complied with the protocol, who received three injections; whose
baseline Pap was normal, ASCUS, or LSIL cases counting starting day after the third vaccination.
ATP-E∗ meansthosesubjectsthatareHPV-DNA-negativeforHPV16/18atstudyentryregardlessofinitialserostatuswiththeHPVtypeassignmentalgorithm
aand used to resolve causation when multiple HPV types were present. 14% of women were seropositive for HPV 16, and 10% were seropositive for HPV 18
at study entry; all were HPV-DNA-negative for HPV 16/18.
Table 7: Eﬃcacy in less than 3-doses [68].
Endpoint Population Vaccine eﬃcacy
(95% CI)
Median
time of
follow-
up
2d o s e s T V C ∗ 84% (50, 96) 4years
1d o s e T V C ∗ 100% (67, 100) 4years
One-year persistence was deﬁned as two positive tests for the same HPV
type in visits 10+ months apart in women negative at enrollment for that
HPV type with no intervening negatives and whose infection occurred after
randomization.
TVC∗ means total vaccinated cohort of women who were HPV 16/18 DNA-
negative at baseline regardless of serostatus and regardless of entry cytology
and who had at least one follow-up datum.
Attack rate of HPV 16/18 infection in the control arm was consistently 4.5–
5/100 women over the study.
4.3. Eﬃcacy in Seropositive Females. Cervarix has excellent
eﬃcacy against CIN 2+ caused by HPV 16/18 in women who
are already seropositive for the same HPV type, but DNA-
negative at the time of initial vaccination (Table 6)[ 67]. As
the meaning of serostatus deﬁned by the current assay meth-
ods for both vaccines has been recently questioned [115],
the data on vaccine eﬃcacy in the set of vaccinated subjects
without current HPV 16/18 infection (DNA-negative for
HPV 16/18) at baseline regardless of serostatus becomes
important. The vaccine eﬃcacy against CIN 2+ caused by
HPV 16/18 regardless of serostatus among all vaccinated
women HPV-DNA-negative for HPV 16/18 at baseline is
99% to 92% with tight 96.1% conﬁdence intervals of 84–
97 [67]. This eﬃcacy is reassuring because population data
indicate that nearly 10% of the 11-12-year-old target age
group has already seroconverted for prior exposure to high-
risk HPV types, potentially due to vertical or horizontal
mother to child transmission [38, 116]. This high eﬃcacy is
supported by its corresponding strong immunologic data.
4.4. Eﬃcacy in Less Than 3 Doses. Vaccine eﬃcacy is
currently deﬁned after three doses are administered. USA
and European data show that less than 20% of 13-year-old
g i r l sh a v er e c e i v e da l lt h r e ed o s e so fv a c c i n e[ 117, 118]w i t h
anecdotal evidence indicating that only a fraction of those
receiving three doses received all three doses within the one
year time span for the expected eﬃcacy to ensue. Catch-up
vaccination in the 19–26 year-old women is also less than
20% [119], a critically cost-eﬀective age group of females if
vaccine eﬃcacy is less than 10 years [81].
Early data show that Cervarix remains 100% eﬃcacious
with just one-dose (Table 7)[ 68]. While this must be proven
for regulatory approval, this property of Cervarix both
simpliﬁesimplementationandlessenscostforcervicalcancer
prevention everywhere.
4.5. Eﬃcacy in Older Women by Immunobridging. Cervarix
studies in women through 55 years have been ongoing
for more than four years with immunogenicity results
very similar to the 10–15-year-old and the 15–26-year-old
population thus bridging to a similar eﬃcacy for the older
aged cohort (Table 8)[ 69–72, 120]. While this indication
has received regulatory approval in 60 countries, the option
to vaccinate a woman older than 26 years appears to be
a promising clinical option for individual women in all
countries.
4.6. No Therapeutic Eﬃcacy. W h i l eC e r v a r i xp r o v i d e sv e r y
higheﬃcacyregardlessofserostatus,Cervarixdoesnotcause
regression of HPV DNA 16/18 infections already present,
nor does Cervarix accelerate progression to CIN 3+ from the
current infection [121].
5. Immunogenicity
As discussed, cost-eﬀectiveness models indicate no cancer
prevention occurs if duration of eﬃcacy is too short. The8 ISRN Obstetrics and Gynecology
Table 8: Factor of antibody titer increase over natural infection titers for each age group by oncogenic HPV type for Cervarix [69–72].
10–15 years old [72] 15–25 years old [70, 71] 26–45 years old [71] 46–55 years old [71]
HPV 16 HPV 18 HPV 16 HPV 18 HPV 16 HPV 18 HPV 16 HPV 18
Month 7 253 170 107 82 230 91 84 57
M o n t h 2 4 4 02 52 22 6 2 81 21 6 8
M o n t h 4 8 2 91 82 01 5 1 8 8 1 1 5
Seroconversion at 48
months: % (95% CI)
100%
(98, 100)
100%
(98, 100)
100%
(98, 100)
100%
(98, 100)
100%
(97, 100)
100%
(98, 100)
100%
(97, 100)
99.4%
(97, 100)
Population is according to protocol, which included females seronegative to HPV 16/18 at baseline who received all three doses of study vaccine or placebo
according to schedule, complied with the blood sampling schedule, and did not become positive for HPV-16/18-DNA during the trial.
Seropositivity at 48 months among women seronegative for HPV 16/18 at baseline, who received Cervarix in the ATP cohort. Seropositivity is deﬁned as
antibody titers ≥8 ELU/mL for HPV 16; ≥7ELU/mL for HPV-18. Measured by type-speciﬁc ELISA testing.
minimum time analyzed is 10 years of eﬃcacy, most use 15-
or 20-year durations; if less than this, the cancers are merely
postponed, not prevented [76, 79–81]. While Cervarix trials
continue to accrue eﬃcacy years beyond the documented
9.4 years, the supplementary and supportive traditional
surrogates of eﬃcacy are immunologic responses, despite
not knowing the full clinical ramiﬁcations of their meaning,
nor the degree of inﬂuence that smoking or hormonal
contraception may cause.
5.1. In-Vitro Head-to-Head Trials between Cervarix and
Gardasil. T helper cells are important for several immune
functions. These include B-cell diﬀerentiation, sustained
memory, activation of recall reactions, and thus anamnestic
responses [122]. T helper cell (CD4+) frequencies at 18
months after ﬁrst vaccination were a robust 93% for
HPV 16 and 79% for HPV 18, signiﬁcantly higher than
the competitor vaccine in head-to-head trials [101, 123];
similarly, Cervarix had superior frequencies of T cells for
HPV 31 and 45 than the competitor vaccine at one month
after the third vaccine dose [122]. HPV 6 and HPV 11 L1-
reactive T cells were induced after Cervarix administration
at similar frequencies as seen in recipients of Gardasil [122].
Protection against genital warts from HPV 6/11 has been
documentedintheCervarixvaccinatedpopulationintheUK
[124].
At 18 months, Cervarix-induced a robust memory B cell
response for HPV 16 in 87% of subjects and for HPV 18 in
75% of subjects, both signiﬁcantly superior to Gardasil [101,
123].
5.1.1. Systemic Antibody Titers in Head-to-Head Trials
between Cervarix and Gardasil. Systemic antibody responses
induced by Cervarix, measured by the pseudovirion-based
neutralisation assay (PBNA), were robust, despite protective
serologic antibody titers having not been deﬁned. Cervarix
maintained a 100% seropositivity for both HPV types with
substantial titers above natural infection for the full 9.4 years
(Figures 4 and 5)[ 125]. When measured in a head-to-head
trial with Gardasil one month after three doses of vaccine,
Cervarix-induced 4-fold more anti-HPV 16 titers and 7-fold
more anti-HPV-18 titers than Gardasil, and at 18 months
Cervarix-induced antibodies were still 2.5-fold higher for
HPV 16 and 5-fold higher for HPV-18 than those induced
by Gardasil in 18–45-year-old women [101, 123]. Head to
head trial antibody measurements in diﬀerent assay systems
forCervarixandGardasilshowedmany-foldhigherresponse
by Cervarix than by Gardasil putting an end to the argument
thatthediﬀerenceinantibodytitersiscausedbytheantibody
measurement systems (Figure 6)[ 126].
5.1.2. Local Antibody Titers in Head-to-Head Trials between
Cervarix and Gardasil. Local antibody titers at the cervical
squamocolumnarjunctionwithinthecervicovaginalmucous
may play an important adjuvant role in the prevention
of HPV 16/18 infection [127]. The value of mucosal
antibodies is vigorously debated ranging from no proven
value in human biologic systems to time-enhanced virion
neutralization because of immediate antibody presence.
Antibodies transudate from the dermal capillary network to
place antibodies directly at the squamocolumnar junction
where basal cell invasion, is most vulnerable [128]. Eighteen
months after vaccination Cervarix-induced cervicovaginal
mucous antibodies to HPV 16 were measurable in 21%
o fw o m e na n dt oH P V1 8i n7 %o fw o m e n .T h i sw a s
signiﬁcantly higher than the 14% and 0% in Gardasil
recipients at the same time point, respectively, in head-to-
head trials [123].
5.2. Immunogenicity in Females with Prior Exposure. Cer-
varix induces equally high anti-HPV 16 and anti-HPV-
18 titers in HPV-DNA-negative women regardless of their
serostatus (Figures 7 and 8)[ 129, 130]. This supports the
eﬃcacy data from seropositive/DNA-negative women. This
data should provide reassurance to physicians and women
that vaccination with Cervarix after HPV exposure will oﬀer
the same high immunological protection as in vaccinated
seronegative/DNA-negative women.
5.3. Immunogenicity of Women Aging 25–55 Years. Table 8
and Figure 9 indicate that even the 46–55-year-old women
mountapeakantibodyresponsetoCervarixthatisatleast50
fold higher than natural infection induces, and this response
stays many-fold higher than natural infection titers through
at least month 48 for both HPV 16 and HPV 18 [71, 131].ISRN Obstetrics and Gynecology 9
Current distribution
Projected distribution
ASCUS LSIL HSIL Cancer
0
5
10
15
20
25
30
N
u
m
b
e
r
o
f
a
b
n
o
r
m
a
l
P
a
p
t
e
s
t
s
p
e
r
y
e
a
r
×
1
0
5
Figure 3: HPV 16 and 18 prevention will reduce cytologic abnor-
malities by small amounts [73]. In a screened population, while the
greatest prophylactic vaccine protection will be in preventing over
70% of cervical cancers, the absolute numbers of cancers available
to prevent are quite small. On the other hand, the estimated
8% reduction in ASCUS and 23% reduction in LSIL will yield
a much larger absolute number of women who are prevented
from further medical work-up [73]. It is this prevention of further
medical follow-up that drives the cost-eﬀectiveness of prophylactic
vaccination in screened populations [73].
5.4. Immunogenicity of Less than Three Doses of Cervarix.
In 9–25-year-old females Cervarix induces the same peak
antibody titers for HPV-16 and 18, measured at month 7
after ﬁrst injection for three doses (given at 0, 1, and 6-
months)asfortwo-doses(givenat0and6-months).Thetwo
dose regimen contained double the antigen concentration at
the 6-month dose [135].
5.5. Immunogenicity in Males. With the opportunity to
prevent other HPV-associated cancers in males, Cervarix has
been trialed in males to document its induced immunologic
responses. Among males 10–18 years old, Cervarix induces
higher peak antibody titers than in females of similar ages.
Speciﬁcally, after three doses in males 10–14 years of age
anti-HPV 16 and anti-HPV-18 titers are higher than those
induced in 10–14-year-old females (Figure 10)[ 132]. Titers
aresuﬃcientlyrobusttosupportimmunobridgingtoeﬃcacy
in males.
5.6. Coadministration with Other Vaccines. The adolescent
platform of vaccination was designed around the revised
recommendations of HPV, pertussis, and meningococcal
vaccination at 11-12 years of age [136]. Coadministration of
vaccines at this age requires data to show both equivalent
immunogenicity and safety as would have been obtained
without co-administration. Cervarix was trialed with a
combined reduced-antigen content diphtheria-tetanus acel-
lular pertussis—inactivated poliovirus vaccine (dTpa-IPV,
Boostrix) in females 10–18 years old seronegative for HPV
16/18 at baseline [133]. The trial showed that titers one
month after the third dose of Cervarix when administered
alone were the same as the titers induced from Cervarix
with Boostrix; these anti-HPV16 and anti-HPV-18 titers
are hundreds of fold higher than natural infection titers
(Figures 11 and 12). Three ongoing trials pair Cervarix with
TDaP (Boostrix) and/or meningococcal conjugate vaccine
(Menactra), Cervarix with hepatitis B vaccine (Engerix
B), and Cervarix with a combination of hepatitis A and
B vaccines (Twinrix) (Clinical Trials registration numbers
NCT00369824, NCT00652938, and NCT00578227, resp.)
[137]. These represent the vaccines currently recommended
in the adolescent platform in the United States.
6.Safety
Safety has been discussed in detail in previous publications
[130, 138]. In general, Cervarix is safe for most women:
adolescent girls, younger women, and older women through
72 years of age [57, 69–72, 129, 139]. Local side eﬀects
of pain, erythema, and induration occur after vaccination
with resolution within 2-3 days. Phase II and phase III
randomized controlled trials (PATRICIA trials) did not
reveal any serious adverse events occurring more often in the
vaccinated group than the placebo group. After 9.4 years of
follow-up, new onset chronic disease did not occur any more
frequently in the vaccine than placebo group. Teratogenic
and pregnancy related side eﬀects have not been identiﬁed
with Cervarix [140, 141], but post-marketing surveillance
will continue to monitor the rate of spontaneous abortion
among Cervarix recipients whose pregnancies occurred
around the time of vaccination [142].
Co-administered vaccines did not produce worse local
injection side eﬀects and did not increase the reporting of
serious adverse events; there was detailed follow-up for 30
days after vaccination and for those subjects who became
pregnant [133].
7.PostMarketingSurveillance
Post-marketing surveillance continues to follow speciﬁc
pregnancy related side eﬀects. In addition the FDA spon-
sors the general Vaccine Adverse Events Reporting System
(VAERS) to periodically reassess vaccine safety, making
changes in recommendations only if the incidence of adverse
events is more than twice the very rare incidence of 1/10,000
women [143]. To date there are only 39 reports in VAERS
after Cervarix administration, 97% of which are non-
serious report dyspnea and fainting [144]. Fainting has been
a recognized outcome after vaccination, especially in the
adolescentpopulation,whichhasledtotherecommendation
of 15 minutes of observation after any HPV vaccination
[109, 145]. There has been one publication of autoimmune
demyelinating neurologic disease that completely resolved
within 3 weeks without sequelae after the second dose of
Cervarix [134].
8.Regulatory Affairs
Cervarix was approved by the USA Food and Drug Adminis-
tration(FDA)inOctober2009.Itiscurrentlylicensedinover10 ISRN Obstetrics and Gynecology
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Figure 4: Sustained anti-HPV-16 titers continue through 9.4 years among ATP cohort for immunogenicity [64, 65]. GMT means geometric
mean titres for anti-HPV-16 neutralising antibodies by pseudovirion-based neutralisation assay (PBNA). ∗Horizontal line represents the
neutralising antibody level in women from a phase III eﬃcacy study who had cleared a natural infection before enrollment. ATP cohort
for immunogenicity means women who met all eligibility criteria, were seronegative at baseline for HPV 16/18 and DNA-negative for 14
oncogenic HPV types at baseline, normal cytology, complied with study procedures in preceding and current studies, and had data available
for at least one vaccine antibody blood sample. PRE means prevaccination.
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Figure 5: Sustained anti-HPV-18 titers continue through 9.4 years among ATP cohort for immunogenicity [64, 65]. GMT means geometric
mean titres for anti-HPV-18 neutralising antibodies by pseudovirion-based neutralisation assay (PBNA). ∗Horizontal line represents the
neutralising antibody level in women from a phase III eﬃcacy study who had cleared a natural infection before enrollment. ATP cohort
for immunogenicity means women who met all eligibility criteria, were seronegative at baseline for HPV 16/18 and DNA-negative for 14
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available for at least one vaccine antibody blood sample. PRE means prevaccination.
100 countries worldwide with over 60 countries approving
Cervarix for women older than 25 years. The vaccine is
approved for use in the USA in females aged 10 years
through 25 years for the prevention of HPV 16/18 attributed
cervicalcancer,CIN2+,adenocarcinomainsitu,andCIN1+
disease [146]. The regulatory approval acknowledges cross-
protection to HPV types beyond HPV 16/18.
The USA based Advisory Committee on Immunization
Practices(ACIP)recommendsroutinevaccinationoffemales
aged 11 or 12 years with 3 doses; the vaccination series
can be started as early as 9 years. Likewise, vaccination is
recommendedforfemalesaged13through26yearswhohave
not been vaccinated previously or who have not completed
a 3-dose series of HPV vaccination. If a female reaches the
age of 26 years before the vaccination series is complete,
remaining doses can be administered after the age of 26
years. The second dose should be administered one to two
months after the ﬁrst dose. The minimum interval between
the ﬁrst and second dose of vaccine is 4 weeks and between
the second and third dose is 12 weeks. The minimum
interval between the ﬁrst and third dose is 24 weeks
[145].ISRN Obstetrics and Gynecology 11
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Figure 6: Comparative anti-HPV-16 and anti-HPV-18 titers mea-
sured in two assays for Cervarix and Gardasil [126]. Immuno-
genicity comparisons between Cervarix and Gardasil one month
after 3rd dose (month 7) in 18–45-year-old women: ELISA versus
cLIA measurement systems. ELISA: enzyme-linked immunosor-
bentassayinELISAunits/mL(EU/mL).cLIA:competitiveLuminex
immunoassay in milliMerck units/mL (mMerckU/mL). GMT
means geometric mean titer.
The product insert recommends Cervarix to be adminis-
tered intramuscularly in three separate shots, with the initial
0.5mL dose being followed by two additional shots at one
and six months [109].
9. Conclusions
Cervarix has the potential to reduce the burden of cervical
cancer in either one or three doses in those females who are
seronegative or seropositive for HPV 16/18. In populations
without organized cervical cancer screening, Cervarix can
lower the incidence of cervical cancer from the current 50–
80/100,000 women to 9.5/100,000 women. In Europe, 18 of
the 27 member states of the European Union have cervical
cancer incidences above 9.5/100,000 (Figure 13)[ 147].
In countries with cervical cancer screening programs,
Cervarixhasthepotentialtoreducethepopulationincidence
of cervical cancer in those subpopulations who do not
participate regularly in the screening programs. In the USA
this would be the Hispanic and Black populations with
current cervical cancer incidences of 12.8 and 11.1 per
100,000, respectively [148].
ThelargestpopulationbeneﬁtofCervarixinthescreened
population, though, is the reduction of abnormal Pap test
results, colposcopies, and excisional treatments. reduction
in CIN 3+ regardless of HPV causation is shown to be
93% for those vaccinated between 16–26 years [114]. In
addition, the beneﬁt of Cervarix in women older than
25 years is to reduce the incidence of CIN 2+, currently
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Figure 7: Geometric mean titers and seropositivity rates measured
by ELISA for anti-HPV-16, by serostatus in women 16–26 years old
[129]. ATP cohort for immunogenicity. Bars show log10 geometric
mean titer and 95% conﬁdence interval. % = proportion of women
seropositive for antigen. For the GMT calculation, seronegative
women were assigned a value of half the assay cutoﬀ level. The
number of women with evaluable blood sample shows the number
of women who were seropositive or seronegative at baseline.
ATP: according to protocol; HPV: human papillomavirus; GMT:
geometric mean titer.
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Figure 8: Geometric mean titers and seropositivity rates measured
by ELISA for anti-HPV-18, by serostatus in women 16–26 years
[129]. ATP cohort for immunogenicity. Bars show log10 geometric
mean titer and 95% conﬁdence interval. % = proportion of women
seropositive for antigen. For the GMT calculation, seronegative
women were assigned a value of half the assay cut-oﬀ level. The
number of women with evaluable blood sample shows the number
of women who were seropositive or seronegative at baseline.
ATP: according to protocol; HPV: human papillomavirus; GMT:
geometric mean titer.
equivalent to the incidence of all other HPV -associated
cancers in women combined (anal, vaginal, vulvar, and
oropharyngeal). Cervarix has the greatest potential, more
than any known vaccine or screening method to reduce the
burdenofcervicaladenocarcinomasinboththescreenedand
unscreened populations by over 90% [60, 66].12 ISRN Obstetrics and Gynecology
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(a) Fold higher than natural infection titers at 48 months after ﬁrst
vaccination: 18-fold higher than NIT for women 26–45 years old, and
11-fold higher for women 46–55 years old [131]
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Figure 9: Antibody titers in women 15–55 years of age seronegative at baseline in the ATP cohort over time [71]. GMT means geometric
mean titre and is shown with 95% conﬁdence intervals; EU/mL = ELISA units per milliliter. Arrows indicate the vaccination time points
(months 0, 1, and 6). Seropositivity is deﬁned as ≥8 EU/mL for anti- HPV-16 and ≥7EU/mL for anti-HPV-18. Natural infection is from the
GMTs in women seropositive DNA-negative for HPV-16 and HPV-18 from the PATRICIA trial [129].
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Figure 10: Seroconversion and antibody response to HPV 16/18 in
malescomparedtofemales[132].GMTmeansgeometricmeantiter
measured at month 7, one month after the third dose of Cervarix.
A l ls u b j e c t sw e r es e r o n e g a t i v ea ts t u d ye n t r y .D a t ab a s e do nA T P
immunogenicity cohort [132]. ATP means according to protocol.
Cervarix induces anti-HPV 16 and anti-HPV-18 titers
in males that exceed titers in similarly aged females, and
Cervarix has a proven duration of eﬃcacy for at least 9.4
years.
10. Expert Commentary
Cervical cancer screening programs have been very success-
ful. Evidence now conﬁrms that decreases in population
participation in screening programs do cause an increased
overall population incidence of cervical cancer [75, 103].
This increase in cervical cancer is also predicted from cost-
eﬀectiveness models which show that high screening partic-
ipation is more important than population vaccination for
minimizing cervical cancer incidence [74]. Cancer incidence
will also increase if vaccine eﬃcacy is time limited and
those vaccinated neglect participating in routine screening
[74, 76, 85].
Should vaccination be an option that women choose
for their cervical cancer protection, Cervarix is an excellent
choice for both screened and unscreened populations due to
its long-lasting protection, its broad protection for at least
ﬁve oncogenic HPV types, the potential to use only one-dose
for the same level of protection, and its safety.
The most eﬃcient use of Cervarix is in countries without
any cervical cancer screening programs where the incidence
of cervical cancer can be reduced to 9.5/100,000 women
by vaccinating young females. This is the public health
target of the World Health Organization (WHO) and most
publichealthauthorities.Inaddition,Cervarixoﬀersthebest
chance of preventing adenocarcinomas of the cervix.
Other options, not public health targets at this time,
but supported by trial data, include vaccinating women at
any age who are not currently infected with HPV 16/18;
this is about 98% of women [20, 55]. A major objectionISRN Obstetrics and Gynecology 13
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Figure 11: Peak anti-HPV 16 titers with Cervarix compared to
Cervarix co-administered with a pentavalent vaccine in seroneg-
ative females 10–18 years old at study entry [133]. Anti-HPV 16
titers were measured one month after the third dose of Cervarix in
the according to protocol immunogenicity cohort of study subjects.
AntiHPV16seroconversionisequivalentinthetwogroupsstudied,
represented by the percentages at the base of the columns. The blue
linerepresentstheanti-HPV16responseinwomen16–26yearsold,
and the red dotted line represents the anti-HPV 16 titers in women
with natural infection who had cleared their infection (natural
infectiontiters).GMTmeansgeometricmeantitershownwith95%
conﬁdenceintervalbars.EUmeansELISAunit.HPVmeanshuman
papillomavirusvaccine,Cervarix,administeredatmonth0,1and6.
HPV+dTpa-IPV means Cervarix co-administered with diphtheria,
tetanus, acellular pertussis and inactive polio vaccine at month 0,
and Cervarix alone administered at months 1 and 6.
to HPV vaccination is the pre-pubescent young age at
which parents are asked to make the decision to vaccinate
their daughters [149]. Public health organizations target this
age group because the data from the vaccine trials show
excellenteﬃcacyinfemaleswhohavenotyetbeenexposedto
HPV: both seronegative and DNA-negative. But the Cervarix
trial data also show excellent eﬃcacy in DNA-HPV-16/18
negative women regardless of serostatus at vaccination. This
is reassuring for the youngest age vaccinees as epidemiologic
datashowthat10%arealreadyseropositivetohigh-riskHPV
types at 11-12 years of age. In addition, the eﬃcacy in both
seronegative and seropositive females who are HPV-DNA-
negative at the time of vaccination is reassuring to females
w h oc h o o s et ob ev a c c i n a t e da ta no l d e ra g e .O l d e ra g e
vaccination is strongly supported by data showing that there
is little beneﬁt of vaccination at 11-12 years of age if the
duration of vaccine eﬃcacy is not at least 15 years [76, 85].
Moreover, much data show that seronegative females may
actually have already seroconverted from a prior exposure to
HPV but their antibody titers have waned and are now too
low to detect. Hence, the conundrum of whether a sexually
active woman is truly seronegative becomes moot with high
Cervarix eﬃcacy regardless of serostatus.
Another important individual health beneﬁt, not sup-
ported by public health authorities at this time, is the
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Figure 12:Peakanti-HPV-18titerswithCervarixcomparedtoCer-
varix co-administered with a pentavalent vaccine in seronegative
females 10–18 years old at study entry [133]. Anti-HPV 18 titers
were measured one month after the third dose of Cervarix in the
according to protocol immunogenicity cohort of study subjects.
AntiHPV18seroconversionisequivalentinthetwogroupsstudied,
represented by the percentages at the base of the columns. The
blue line represents the anti-HPV-18 response in women 16–26
years old, and the red dotted line represents the anti-HPV-18 titers
in women with natural infection who had cleared their infection
(natural infection titers). GMT means geometric mean titer shown
with 95% conﬁdence interval bars. EU means ELISA unit. HPV
means human papillomavirus vaccine, Cervarix, administered at
month0,1and6.HPV+dTpa-IPVmeansCervarixco-administered
with diphtheria, tetanus, acellular pertussis and inactivated polio
vaccine at month 0,and Cervarix alone administered at months 1
and 6.
vaccination of older women who are in screening programs
[150, 151]. The incidence of CIN 2+ among women older
than 45 years is estimated to be 385/100,000 women [47].
While no one knows how quickly incident CIN 2+ in older
women will progress to cervical cancer, clinical prudence
indicates excisional treatment for this lesion. This incidence
is equivalent to the combined incidence of vaginal, vulvar,
anal,andoropharyngealcancerscausedbyHPVinwomenof
all ages, also 385/100,000 women [152]. If vaccine protection
is thought useful for these latter HPV-associated cancers,
then it is logical that vaccine protection would also be useful
for older women in countries with screening programs,
wherethetruebeneﬁtofvaccinationisthepreventionofnew
CIN 2+.
Cervarix is particularly pertinent for the prevention of
CIN 2+ in women older than 45 years because 70% of
these CIN 2+ are caused by high-risk HPV types other
than HPV 16 [47]. The additional high-risk-type protection
against HPV 45, 31, and 33 targets the diﬀerent HPV type
distribution seen in precancerous disease of older women.
Even women older than 55 years continue to accrue incident
oncogenic HPV infections that progress to CIN 3 disease
[47]; hence, being able to vaccinate women through 55 years
adds individual, if not population, protection.14 ISRN Obstetrics and Gynecology
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Figure 13: Age standardised mortality from and incidence of cervical cancer in the 27 Member States of the EU (2004) [134]. Dotted line
represents the estimated incidence of cervical cancer that Cervarix can achieve at 9.5/100,000 women. Countries with incidences (blue bar)
to the right of the dotted line may have a population beneﬁt reduction in cervical cancer incidence.
CervarixpreventsanalHPVinfectioninwomenforHPV
16, 18, 31, 33, and 45 [153] ,m o r ep o s s i b l ea n a lc a n c e r
prevention than the competitor vaccine, Gardasil.
Finally, while male uses of Cervarix are not recognized by
regulatory authorities at this time, should HPV vaccination
for male HPV-associated cancers become a health priority,
Cervarix has excellent immunogenicity and safety in males.
11. Five-YearView
Within ﬁve years Cervarix will have completed its extension
trial designed to determine long-term immunogenicity,
eﬃcacy, and safety past 15 years. Finland has enrolled over
20,000 16-17-year-old women in the PATRICIA trial who are
continuing to be followed. Their data will be linked with the
Finnish cancer registry and provide CIN 3/cancer incidence
rates between the vaccinated and unvaccinated women at 10
years after initial PATRICIA enrollment providing evidence
of eﬃcacy past the 15-year threshold cost-eﬀectiveness
models have identiﬁed [154].
While vaginal and vulvar lesions are a very small
proportion of HPV-associated anogenital diseases, and the
PATRICIA studies did not include vulvar or vaginal end-
points, the ad hoc collection of VAIN 2+ and VIN 2+ data
showvaccineeﬃcacyof54%intheTVC-Npopulation[155].
Because of the novel adjuvant formulation of Cervarix,
this HPV vaccine may have a unique role in protecting
those with autoimmune disorders. Trials enrolling women
with HIV, juvenile idiopathic arthritis, systemic lupus ery-
thematosus, and juvenile dermatomyositis (NCT00815282)
are ongoing and expected to have reportable results within
the next ﬁve years.
The development of second-generation vaccines contin-
ues as solid global evidence that the high-risk types of most
importanceincludetheﬁvetypesalreadycoveredbyCervarix
and three additional types (HPV 35, 52, and 58) [60]. Of
more importance is the possibility of conjoining the L1 and
L2 VLPs to develop a pan-protective vaccine whose one-
dose produces at least 15 years of eﬃcacy against all CIN
2+. With this future-generation vaccine, it would be possible
to discuss the discontinuation of routine cervical cancer
screening programs.
12. Key Points
(i) Cervical cancer prevention, the main purpose of
HPV vaccination, is best served by continued par-
ticipation in Pap screening programs with optional
vaccination.
(ii) Cervarix’s pertinent strengths are
(a) its ability to prevent CIN 2+caused by ﬁve
oncogenicHPVtypesforatleast9.4years[125],ISRN Obstetrics and Gynecology 15
(b) its high and sustained T- and B-cell immuno-
logic responses, including serum antibody
titers, for HPV-16 and 18 that last at least 8.4
years,
(c) its ability to prevent CIN 2+ caused by HPV
16/18 in women DNA-negative for HPV 16/18
but seropositive (already exposed to HPV
16/18) equally well as in seronegative females
for at least 8.4 years,
(d) itsabilitytopreventCIN2+inone-doseequally
well as in three doses for at least 4 years,
(e) its ability to immunobridge CIN 2+ eﬃcacy in
women through 55 years
(f) its ability to prevent about one in ﬁve abnormal
Pap tests and to prevent nearly 70% of the
excisional treatments in women with access to
screening.
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